BRIEF-FDA accepts Lundbeck drug labeling for review

COPENHAGEN, April 30 Wed Apr 30, 2014 9:12am EDT

Related Topics

COPENHAGEN, April 30 (Reuters) - Danish pharmaceutical company Lundbeck said on Wednesday: * United States' Food and Drug Administration has accepted for review a supplemental new drug application (SNDA) for the proposed expanded labeling of schizophrenia drug Abilify Maintena, which is developed by Otsuka Pharmaceutical and Lundbeck. Source text for Eikon: